Trial
NCT03661047
OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Harvard School of Public Health (HSPH)
Condition
Colon Cancer
Intervention
AMR101 (VASCEPA, icosapent ethyl)
Why stopped
Study will be closed due to zero enrollment in over 2 years.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-17